摘要
目的:通过数据挖掘和关联分析等方法,寻找古方中使用珍稀中药人参的用药特点与配伍规律,以验证并拓宽其临床应用。方法:从中医方剂数据中筛选出用量及功效明确、组成含有人参的方剂2420首。通过Apriori算法及聚类分析对方剂进行数据挖掘。结果:Apriori关联分析得出,人参-甘草,人参-白术,人参-当归,是最常用的二联用药。人参-白术、甘草,人参-白芍、当归,当归-白芍、人参,是最常用的三联用药。小剂量人参与甘草、白术配伍,大剂量人参与甘草配伍;通过聚类提取出4个因子,提取出的方剂分别具有止痛、温补肾阳、降逆止呕、补气行血的功效。结论:人参用量不宜过大,与人参配伍的中药以调和人参药性、治疗脾胃虚寒、温肾散寒止痛4个方面的作用为主,为临床使用与实验研究提供理论依据与实验思路。
Objective:To look for the characteristics and compatibility of the rare traditional Chinese medicinal Radix Ginseng used in ancient prescriptions based on data mining correlation analysis and other methods,so as to verify and broaden the clinical use of it.Methods:A total of 2420 prescriptions containing Radix Ginseng were selected from the traditional Chinese medicine prescription data with clear dosage and efficacy.Data mining of prescription was carried out through Apriori algorithm and cluster analysis.Results:Correlation analysis of Apriori showed that Radix Ginseng-liquorice,Radix Ginseng-atractylodes atractylodes,Radix Ginseng-angelica,were the most commonly used dual drug.Radix Ginseng-atractylodes root,Radix Glycyrrhizae,Radix Ginseng-radix paeoniae alba,Radix Angelicae Sinensis-radix Paeoniae Alba,Radix Ginseng were the most commonly used triple drug.Small doses of people involved in the compatibility of Radix Glycyrrhizae and Rhizoma Atractylodis Macrocephalae.High-dose Radix Ginseng participate in the compatibility of Radix Glycyrrhizae to extract four factors through clustering and the extracted formulas had the following effects:analgesia,warming kidney-yang,reducing and anti-vomiting,and replenishing qi and blood.Conclusion:The dosage of Radix Ginseng should not be too large.The traditional Chinese medicine compatible with Radix Ginseng is mainly used to harmonize the medicinal properties of Radix Ginseng,treat the deficiency and cold of spleen and stomach,warm the kidney,disperse cold and relieve pain,providing theoretical basis and experimental thinking for clinical use and experimental research.
作者
王超杰
刘甜甜
曹明明
吴飘
刘琪
陈晨
WANG Chaojie;LIU Tiantian;CAO Mingming;WU Piao;LIU Qi;CHEN Chen(Postfraduate School,Heilongjiang University of Chinese Medicine,Harbin 150000,China;The Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200137,China;The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine,Harbin 150000,China)
出处
《世界中医药》
CAS
2022年第14期2066-2070,2074,共6页
World Chinese Medicine
基金
黑龙江省卫生计生委科研课题(2018234)。
